The significance of biomarkers in the blood in the diagnosis and the course of Alzheimer*s disease

Recruiting

Conditions: Alzheimers disease
10012272

Registration Number: NL-OMON34678

Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

Patient inclusion criteria:
- Patients with Alzheimer's disease
- Mentally competent AD patient [Clinical Dementia Rating (CDR) scale 1]
- The diagnosis of probable Alzheimer's disease* should be made according to the NINCDS-
ADRDA criteria.
- Patients or carers should agree with the study (written informed consent is required form
patients or their carers).;Inclusion criteria control group (healthy subjects in group A):
- Men or women without cognitive or psychiatric disorders
- Mini-Mental State Examination (MMSE) score >= 28

Exclusion Criteria

Patient exclusion criteria:
- Mentally incompetent AD patient [Clinical Dementia Rating (CDR) scale 2 and 3]
- Patients with infection or inflammatory disease less than 1 months ago.
- Patients with active malignancy.
- Patients with autoimmune disease (e.g. temporal arteritis, polymyalgia rheumatica).
- Patients who use immune modulating drugs (e.g. Immunocyanin, interferon gamma, immunoglobulin).
- Patients with renal dysfunction (MDRD <50)
- Patients with liver impairment
- Patients with decreased serum albumin <25 g / l;Exclusion criteria control group:
- Conform the patient exclusion criteria

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Descriptives (gender, age, education level, demographics)<br /><br>- Biochemical biomarkers: neopterin, total amino acid spectrum, HVA, BDNF and<br /><br>S-100B<br /><br>- Comorbidity (CIRS-G)<br /><br>- Drug use<br /><br>- MMSE score, neuropsychological examination and MRI cerebrum<br /><br>- The Clinical Dementia Rating (CDR) scale<br /><br>- Evolution: intercurrent diseases</p><br>

Secondary Outcome Measures